Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.64 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | ILK | Q13418 | 2/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22249489 | 0.90 | NLRP3 (0.67) | NLRP3PRKACAAPP | |
| SCHEMBL20651423 | 0.84 | NLRP3 (0.46) | NLRP3PRKACACLK4CYP1A2CYP3A4 | |
| SCHEMBL22249505 | 0.82 | NLRP3 (0.64) | NLRP3CYP1A2CYP3A4APP | |
| SCHEMBL22249577 | 0.81 | NLRP3 (0.75) | NLRP3APP | |
| SCHEMBL23513877 | 0.80 | NLRP3 (0.77) | NLRP3APP | |
| SCHEMBL22249404 | 0.80 | NLRP3 (0.73) | NLRP3CYP1A2APP | |
| SCHEMBL22249556 | 0.80 | NLRP3 (0.81) | NLRP3APP | |
| SCHEMBL22249490 | 0.79 | NLRP3 (0.72) | NLRP3APP | |
| SCHEMBL22249557 | 0.79 | NLRP3 (0.79) | NLRP3CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL28738541 | 0.79 | NLRP3 (0.78) | NLRP3APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | NLRP3 1/4885PRKACA 2012/4885CLK4 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.